Sirolimus Pharma Grade API is a triene macrolide immunosuppressant isolated from Streptomyces hygroscopicus, identified as CAS 53123-88-9, molecular formula C₅₁H₇₉NO₁₃, and molecular weight 914.17 g/mol. The material is supplied as a white to off-white crystalline powder in process variants that distinguish micronized oral grade, non-micronized oral grade, and injectable grade. The product is offered under manufacturer-specific model designations that link to the active substance master file, batch record, and certificate of analysis; a representative code structure is [manufacturer prefix]-SIR-[oral/injectable]-[particle size target]. Model codes are not pharmacopoeial designations and do not alter the controlling release requirements. The micronized grade is intended for low-dose tablet, capsule, and granule manufacturing, while the injectable grade is controlled for endotoxin, bioburden, and particulate burden. Release testing is performed by high-performance liquid chromatography against a qualified reference standard with UV detection at 278 nm. The substance is practically insoluble in water, soluble in ethanol and methylene chloride, and susceptible to hydrolytic and oxidative degradation; therefore, specification limits follow current USP-NF Sirolimus monograph and ICH Q3A impurity qualification thresholds.

The same API lot cannot be automatically used for oral and injectable manufacture. Injectable material requires additional controls under USP <71>, USP <85>, USP <788>, and USP <790>. Oral non-sterile grades are controlled for microbial quality under USP <1111> categories for non-sterile oral products. The primary dosage-form targets are immediate-release tablets, capsules, granules, oral liquids, and injectable dispersions. Clinical application is immunosuppression, particularly prophylaxis of organ rejection in renal transplant and selected pulmonary indications; however, formulation use must follow approved labeling and regulatory filings for each jurisdiction.

What Release, Stability, and Impurity Controls Apply to Sirolimus for Oral and Injectable Formulations?

Release specifications for Sirolimus Pharma Grade API include identification by infrared absorption spectrophotometry and HPLC retention time, assay 98.0–102.0% on the anhydrous and solvent-free basis, water content by USP <921> Karl Fischer titration, residue on ignition by USP <281>, and residual solvents by USP <467> with ICH Q3C limits. Elemental impurities follow ICH Q3D; acceptance criteria for lead, cadmium, arsenic, mercury, nickel, and chromium are assigned using the permitted daily exposure for the finished dosage form. Related substances are limited by ICH Q3A. Specified degradation products, individual unknown impurities, and total impurities are quantitated against the response factor for sirolimus at 278 nm. Because sirolimus is prone to oxidative degradation, the API is packaged under nitrogen in double low-density polyethylene bags inside an aluminium laminate container. For injectable grades, bacterial endotoxins are determined by USP <85>; the acceptance limit is calculated from the K/M equation, where K is 5 EU/kg/h for intravenous administration and M is the maximum dose of sirolimus per kilogram per hour. Sterility of the injectable API is not a substitute for terminal sterilization or aseptic filtration during finished-product manufacture.

For low-dose solid oral dosage forms, particle size control is not a peripheral analytical parameter; it directly determines blend uniformity and dissolution rate. Sirolimus is formulated at strengths as low as 0.5 mg or 1.0 mg, and the micronized API is typically controlled by laser diffraction according to ISO 13320. A D90 limit of ≤10 µm is common for direct compression and dry granulation routes, while a D50 limit of ≤5 µm may be required when the drug load is below 0.5% w/w. Unmicronized material with D90 above 50 µm can segregate in low-shear tumble blenders and produce content uniformity failures under USP <905>. Dry granulation via roller compaction is preferred over wet granulation when particle size must be preserved, because aqueous granulation can cause partial dissolution and recrystallization that shifts particle size distribution and changes compressibility. If wet granulation is unavoidable, the granulating fluid is added at a controlled rate in a high-shear granulator with jacket temperature below 25°C, and the wet mass is dried at ≤40°C to limit oxidative degradation; published data for this specific configuration is limited. The final blend for capsule filling is evaluated for flow, compressibility, and segregation potential using a Flodex or ring shear tester. Tablet compression should target immediate-release tablet hardness of 3–7 kp, with friability below 1.0% per USP <1216>.

Sirolimus has a melting point of approximately 183–185°C. Although the melting point is above conventional hot-melt extrusion temperatures, thermal stress screening is still required because the macrocyclic lactone ring can degrade under oxidative conditions. Milled API is stored in double low-density polyethylene bags with desiccant and analyzed for amorphous content by X-ray powder diffraction or modulated differential scanning calorimetry. A specification for crystallinity may include no broad amorphous halo greater than 5% amorphous content, but the limit is formulation-specific. During capsule filling, a two-step geometric dilution with lactose monohydrate is used; the first pre-blend is passed through a 500 µm sieve and then blended in a bin blender at 10–15 rpm for 15–30 min. Over-blending can increase electrostatic segregation and is challenged with multiple sampling points to satisfy USP <905>.

When Sirolimus Moves from API Powder to Tablet, Capsule, or Granule Dosage Forms, Which Process Thresholds Are Critical?

Tablet manufacturing for sirolimus presents two competing constraints: low aqueous solubility and the need for high content uniformity. Milling to a D90 of ≤10 µm increases surface area and improves dissolution, but excessive micronization can raise electrostatic charge and reduce bulk density to 0.15–0.35 g/cm³. This requires control of electrostatic discharge during screening and blending, particularly at relative humidity below 30%. Excipient selection for direct compression typically includes lactose monohydrate or microcrystalline cellulose as bulking agents, croscarmellose sodium or sodium starch glycolate as disintegrants, and colloidal silicon dioxide as a glidant at 0.2–0.5% w/w. Dissolution testing should follow USP <711> with a discriminating medium; because sirolimus is practically insoluble in water, 0.4% sodium lauryl sulfate in phosphate buffer at pH 6.8 is often used during development, but the official medium is defined in the approved application and must be validated against in vivo performance. Capsule filling of sirolimus granules requires tight control of granule size distribution; a typical target is 100–600 µm for capsules and 100–850 µm for tablet granulation, with fines below 10% to prevent feed variability in dosator or tamping pin machines. If roller compaction is used, ribbon density is monitored; ribbons with relative density above 0.85 may reduce compressibility after milling, while ribbons below 0.55 may generate excess fines. These values are route-dependent and are established with a factorial design rather than adopted as fixed universal limits.

Oral bioavailability of sirolimus from an oral solution is approximately 14% relative to intravenous administration in fasting adult renal transplant patients, with substantial interindividual variability. This bioavailability constraint reinforces the need for particle size and dissolution control in solid oral dosage forms. Punch filming and sticking have been reported when magnesium stearate is used above 1.0% w/w or when compression force exceeds 15 kN; the phenomenon is formulation-specific and is evaluated by monitoring ejection force and tablet surface roughness on production presses. Content uniformity acceptance value under USP <905> is controlled to ≤15.0; for low-dose sirolimus tablets, in-process control should achieve an acceptance value below 10.0 to allow for assay variation. The API should not be combined with strong oxidizing agents or alkaline excipients, because lactone ring hydrolysis under basic pH generates seco-acid degradation products.

Injectable-Grade Sirolimus: Endotoxin, Particulate, and Solvent System Constraints

Sirolimus injectable manufacturing does not begin with simple aqueous solubilization. The free drug has an aqueous solubility below 0.01 mg/mL, so injectable formulations require a co-solvent system, a surfactant, or a nanoparticle carrier. In non-aqueous or mixed solvent systems, the API may be dissolved in dehydrated alcohol and a surfactant such as polysorbate 80, then diluted with water for injection prior to administration; the exact solvent composition is product-specific. The API is sterilized by aseptic filtration through a membrane with a pore size of 0.22 µm or sterilized by radiation where stability permits. Particulate matter limits for the finished injectable are defined in USP <788> for subvisible particles and USP <790> for visible particles; for large-volume parenterals, the limits are ≥10 µm particles not more than 25 per mL and ≥25 µm particles not more than 3 per mL. For small-volume parenterals, the specific test conditions and acceptance criteria differ and are based on labeled volume. Injectable-grade Sirolimus API must have controlled endotoxin levels; a typical drug substance limit is assigned by dividing the maximum safe endotoxin dose by the maximum dose of sirolimus per kilogram per hour.

Filter compatibility testing is required before manufacture. Sirolimus can adsorb to hydrophobic membranes; a PVDF or PES membrane is typically evaluated, and nylon filters may cause significant drug loss. The product should be protected from light under ICH Q1B photostability conditions. Dissolved oxygen in the formulation vehicle is reduced by nitrogen sparging to below 2 mg/L where feasible. Terminal sterilization should achieve a sterility assurance level of 10^-6 where the formulation can withstand the process; otherwise, aseptic filtration and aseptic filling under sterile conditions are required. Injectable-grade sirolimus is not interchangeable with oral-grade material solely on the basis of chemical assay.

Comparative Risk Boundaries Against Research-Grade Sirolimus and Other mTOR Inhibitor APIs

Differences between pharma-grade Sirolimus API and research-grade or unregistered material are concentrated in three areas: particle size distribution, residual solvent and impurity control, and microbiological or endotoxin status. Research-grade sirolimus may be sold as a lyophilized solid with HPLC purity of ≥95%, while pharma-grade material is released with assay 98.0–102.0% and ICH Q3A-qualified impurities. Particle size is often unreported for research-grade lots, whereas pharma-grade micronized lots include a certificate of analysis with laser diffraction D10, D50, and D90 values. For oral capsule or tablet manufacture, use of research-grade material can shift dissolution and content uniformity results without a corresponding change in formulation, because the particle size distribution is not controlled. For injectable manufacture, research-grade material is generally unsuitable due to the absence of bacterial endotoxin data under USP <85> and the lack of a documented sterility or bioburden profile. Compared with other mTOR inhibitor APIs such as everolimus or temsirolimus, sirolimus has a longer terminal half-life and different metabolic liability, but the formulation-grade differences are not solely clinical; they are controlled through physicochemistry, impurity profiles, and residual solvent limits. Everolimus has a distinct polarity and requires different chromatographic conditions; temsirolimus is an ester prodrug intended for injectable use and is not interchangeable with sirolimus for compounding or manufacture.

Sirolimus Pharma Grade API for tablet, capsule, granule, injection, oral and injectable use therefore differs from lower-grade material by the presence of validated analytical controls, defined particle size distribution, residual solvent and elemental impurity compliance, and route-specific endotoxin and microbial limits. The manufacturer-specific model designation links these controls to a batch record, but the grade-neutral technical profile remains governed by the current pharmacopoeial monographs and ICH quality guidelines.